Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/9/2025 | $53.00 | Buy | BofA Securities |
| 9/17/2025 | $45.00 | Overweight | Barclays |
| 9/15/2025 | $51.00 | Outperform | Leerink Partners |
| 8/21/2025 | $50.00 | Buy | Jefferies |
| 7/30/2025 | $53.00 | Strong Buy | Raymond James |
| 7/17/2025 | Overweight | Cantor Fitzgerald | |
| 11/26/2024 | $40.00 → $50.00 | Buy | H.C. Wainwright |
| 10/7/2024 | $30.00 → $35.00 | Buy | H.C. Wainwright |
SCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
424B5 - Scholar Rock Holding Corp (0001727196) (Filer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
BofA Securities initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $53.00
Barclays initiated coverage of Scholar Rock with a rating of Overweight and set a new price target of $45.00
Leerink Partners initiated coverage of Scholar Rock with a rating of Outperform and set a new price target of $51.00
Completed constructive and collaborative in-person Type A meeting with U.S. Food and Drug Administration (FDA) on November 12th for apitegromab biologics license application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA) Catalent Indiana, LLC (part of Novo Nordisk) participated in the Type A meeting in person and presented the progress made in implementing the remediation plan; confirmed to FDA that the site is on-track to be reinspection ready by the end of this year Resubmission of BLA and U.S. launch following approval of apitegromab for children and adults with SMA anticipated in 2026 Timelines accelerated with additional apitegromab U.S. fil
Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 17,143 shares of common stock and inducement restricted stock units, covering an aggregate of 12,857 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used exc
Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Tuesday, November 18 at 3:30 p.m. GMT in London, UK. A live webcast of the event will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
Completed constructive and collaborative in-person Type A meeting with U.S. Food and Drug Administration (FDA) on November 12th for apitegromab biologics license application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA) Catalent Indiana, LLC (part of Novo Nordisk) participated in the Type A meeting in person and presented the progress made in implementing the remediation plan; confirmed to FDA that the site is on-track to be reinspection ready by the end of this year Resubmission of BLA and U.S. launch following approval of apitegromab for children and adults with SMA anticipated in 2026 Timelines accelerated with additional apitegromab U.S. fil
Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 17,143 shares of common stock and inducement restricted stock units, covering an aggregate of 12,857 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used exc
Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Tuesday, November 18 at 3:30 p.m. GMT in London, UK. A live webcast of the event will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the
- Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co